The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of 1,25-Dihydroxy Vitamin D Assay

12 Dec 2014 07:00

RNS Number : 5807Z
Immunodiagnostic Systems Hldgs PLC
12 December 2014
 



12 December 2014

 

 

Immunodiagnostic Systems Holdings plc.

 

Launch of Fully Automated 1,25-Dihydroxy Vitamin D Assay

 

 

Immunodiagnostic Systems Holdings plc (IDS), a leading solution provider to the clinical laboratory diagnostic market, today announced it has received European CE Mark declaration for the IDS-iSYS 1,25 VitDXp assay - a fully automated assay for use with the IDS-iSYS Multi-Discipline Automated System.

 

The IDS-iSYS 1,25 VitDXp assay assesses 1,25-Dihydroxy Vitamin D status and deficiencies associated with renal disease and disorders of calcium metabolism. Market value of 1,25-Dihyroxy Vitamin D testing is estimated to be circa £15 million per annum in Europe.

 

Patrik Dahlen, CEO of IDS, said: "Continuing IDS's heritage and expertise in endocrinology and Vitamin D testing, the IDS-iSYS 1,25 VitDXp uses a proven and trusted technology to fully automate purification and quantification of 1,25-Dihydroxy Vitamin D. The excellent assay stability, walk away convenience and ease-of-use provides laboratories significant workflow and productivity advantages."

 

Available now, IDS offers laboratories evaluating calcium metabolism and Vitamin D deficiencies a comprehensive, fully automated solution.

 

For further information:

 

Immunodiagnostic Systems Holdings plc

Tel : +44 (0)191 5190660

Patrik Dahlen, CEO

Chris Yates, CFO

Peel Hunt LLP

Tel : +44 (0)207 418 8900

James Steel / Jock Maxwell Macdonald

FTI Consulting

Tel : +44 (0)203 727 1000

Ben Atwell / Simon Conway / Mo Noonan

 

 

About Immunodiagnostic Systems Holdings PLC

The Group's vision is to be a leading solution provider to the clinical laboratory diagnostic market. IDS's strategy is focused on developing, internally and through partnership, its automated assay menu for its proprietary automated immunoassay analyser, the IDS-iSYS system. Internally the Group is focused on developing an endocrinology excellence menu and externally IDS works with partners to develop assay panels in complementary indication fields. The Group sells its products primarily in the clinical laboratory market across a range of customers from reference laboratories to physician office laboratories. IDS has field sales forces in certain European countries, including France and Germany, the United States and Brazil and works with distributors in other markets including China, Italy and Spain.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCTBBJTMBTBTJI
Date   Source Headline
6th Dec 20182:59 pmRNSDirector/PDMR Shareholding
23rd Nov 20185:04 pmRNSHalf-year Report
19th Oct 20185:18 pmRNSH1 Trading Update
4th Sep 20188:00 amRNSCompletion of Share Buyback
30th Aug 20187:00 amRNSProposed Share Buyback
7th Aug 20185:48 pmRNSTransaction in Own Shares
7th Aug 20187:00 amRNSTransaction in Own Shares
1st Aug 20186:06 pmRNSTransaction in Own Shares
31st Jul 20186:02 pmRNSTransaction in Own Shares
26th Jul 20185:59 pmRNSResult of AGM
26th Jul 20187:00 amRNSAGM Statement
11th Jul 20185:33 pmRNSTransaction in Own Shares
20th Jun 20187:05 amRNSPublication of Annual Report and Accounts
20th Jun 20187:00 amRNSFinal Results
13th Jun 20185:07 pmRNSTransaction in Own Shares
6th Jun 20188:04 amRNSTransaction in Own Shares
20th Apr 20184:35 pmRNSTrading Statement
12th Apr 20185:21 pmRNSTransaction in Own Shares
6th Apr 20185:47 pmRNSTransaction in Own Shares
5th Apr 20182:16 pmRNSTransaction in Own Shares
29th Mar 20186:25 pmRNSDirector/PDMR Shareholding
29th Mar 20186:21 pmRNSDirector/PDMR Shareholding
29th Mar 20181:32 pmRNSLaunch of two new automated assays
29th Mar 20187:00 amRNSTransaction in Own Shares
26th Mar 20185:08 pmRNSTransaction in Own Shares
23rd Mar 20183:59 pmRNSTransaction in Own Shares
21st Mar 20185:50 pmRNSDirectorate Change
21st Mar 20181:08 pmRNSDirector/PDMR Shareholding
1st Mar 20184:50 pmRNSTransaction in Own Shares
22nd Feb 20185:02 pmRNSTransaction in Own Shares
21st Feb 20185:30 pmRNSTransaction in Own Shares
15th Feb 20185:20 pmRNSTransaction in Own Shares
13th Feb 201812:13 pmRNSTransaction in Own Shares
12th Feb 20181:22 pmRNSTransaction in Own Shares
6th Feb 20184:49 pmRNSTransaction in Own Shares
5th Feb 20183:19 pmRNSTransaction in Own Shares
2nd Feb 20182:47 pmRNSTransaction in Own Shares
24th Jan 20181:21 pmRNSTransaction in Own Shares
16th Jan 20187:00 amRNSPartnership Agreement with Technogenetics
15th Jan 20184:45 pmRNSTransaction in Own Shares
27th Dec 20175:16 pmRNSTransaction in Own Shares
24th Nov 20174:30 pmRNSHalf-year Report
23rd Nov 20175:15 pmRNSTransaction in Own Shares
14th Nov 201712:06 pmRNSTransaction in Own Shares
13th Nov 20175:37 pmRNSTransaction in Own Shares
2nd Nov 20176:05 pmRNSTransaction in Own Shares
1st Nov 20174:29 pmRNSAdditional Listing
1st Nov 20174:05 pmRNSTransaction in Own Shares
31st Oct 20176:22 pmRNSDirectorate Change
31st Oct 20176:03 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.